The Top 5 Biosimilars Articles for the Week of September 10

Article

The Center for Biosimilars® recaps the top news for the week of September 10, 2018.

Transcript

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of September 10.

Number 5: While biosimilar filgrastim and biosimilar pegfilgrastim are effective in reducing the incidence of neutropenia, adverse events were shown in a recent study to be higher in patients who receive pegfilgrastim.

Number 4: Xbrane Biopharma has announced its intention to shift its focus from generic drugs to biosimilars.

Number 3: Newly published study results show that switching to Retacrit was noninferior to continuing treatment with Epogen.

Number 2: The United Kingdom is hoping to bring more biosimilar developers’ phase 3 trials to the nation’s National Health Service.

Number 1: The FDA’s Oncologic Drugs Advisory Committee will meet next month to discuss Celltrion’s rituximab biosimilar.

Finally, last week, our e-newsletter asked whether you think that biosimilar should be approved without the need for phase 3 studies.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Related Content
© 2023 MJH Life Sciences

All rights reserved.